← Leaderboards
Brian Kearney
Exavir Therapeutics Inc.
$3,049,975
Attributed
$3,049,975
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,049,975 · 1
By mechanism
R44$3,049,975 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Hiv/Aids”
- Jessica Holden · Technical Resources International, Inc.$37,843,443
- Bambra Stokes · Ppd Development Lp$17,155,112
- Amber Mallory · Texas Biomedical Research Institute$8,000,000
- Shaunna Shen · Duke University$7,747,008
- Valentina Stosor · Northwestern University At Chicago$3,948,555
- Dhiraj Kumar Singh · Texas Biomedical Research Institute$3,900,756
Research focus
Hiv/AidsIn VitroDrug Resistance DevelopmentHiv-1Infection RateInjectionsDrug DevelopmentAdolescentHealth Care FacilityHigh RiskHiv InfectionsInfectionAdultInjectableChemistryAnti-Retroviral AgentsClinical TrialsClinic VisitsFirst-In-HumanGuidelinesCanis FamiliarisDoseAids PreventionIn Vivo
Grant awards (3)
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies$1,000,000
R44 · FY2025 · AI · contact PI
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies$1,000,000
R44 · FY2024 · AI · contact PI
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies$1,049,975
R44 · FY2023 · AI · contact PI